The genioglossus is innervated by the medial branch of the hypoglossal nerve (CN XII). Studies in decerebrate animal preparations 2,3 and freely moving animals during natural sleep 4 have shown that direct application of serotonin to the hypoglossal motor nucleus can augment hypoglossal nerve activity and genioglossus electromyographic (EMG) activity. Serotonin receptors of the 5-HT 2A type on the hypoglossal motor nuclei are thought to be the predominant receptor mediating this effect. 5 The effects of systemic increases in serotonin on hypoglossal/genioglossus activity appear to be relatively more complex. Stimulation of different types of serotonin receptors in the central nervous system or periphery 6 could have multiple effects on global genioglossus activity. Serotonin does not cross the blood-brain barrier. However, serotonin precursors (tryptophan, 5-hydroxytryptophan) 7 , selective serotonin reuptake inhibitors [SSRIs], and serotonin-receptor agonists do cross into the central nervous system and can potentially increase genioglossus activity by increasing local serotonin levels or stimulating serotonin receptors. Recent evidence suggests that blockade of the serotonin receptor type 3 can also increase hypoglossal activity. 8 This is believed to occur by action at the nodose ganglion. In one study, ondansetron, a 5-HT 3 receptor blocker, decreased the apnea-hypopnea index in the English bulldog. 9 Hypoglossal activity is also augmented by norepinephrine, 10 although this effect has not been studied as extensively as it has been with serotonin.
INTRODUCTION

THE ACTIVITY OF THE GENIOGLOSSUS, A TONGUE PROTRUDER, ALONG WITH OTHER UPPER AIRWAY MUSCLES IS IMPORTANT FOR MAINTAINING UPPER
AIRWAY PATENCY DURING SLEEP. 1 The genioglossus is innervated by the medial branch of the hypoglossal nerve (CN XII). Studies in decerebrate animal preparations 2, 3 and freely moving animals during natural sleep 4 have shown that direct application of serotonin to the hypoglossal motor nucleus can augment hypoglossal nerve activity and genioglossus electromyographic (EMG) activity. Serotonin receptors of the 5-HT 2A type on the hypoglossal motor nuclei are thought to be the predominant receptor mediating this effect. 5 The effects of systemic increases in serotonin on hypoglossal/genioglossus activity appear to be relatively more complex. Stimulation of different types of serotonin receptors in the central nervous system or periphery 6 could have multiple effects on global genioglossus activity. Serotonin does not cross the blood-brain barrier. However, serotonin precursors (tryptophan, 5-hydroxytryptophan) 7 , selective serotonin reuptake inhibitors [SSRIs] , and serotonin-receptor agonists do cross into the central nervous system and can potentially increase genioglossus activity by increasing local serotonin levels or stimulating serotonin receptors. Recent evidence suggests that blockade of the serotonin receptor type 3 can also increase hypoglossal activity. 8 This is believed to occur by action at the nodose ganglion. In one study, ondansetron, a 5-HT 3 receptor blocker, decreased the apnea-hypopnea index in the English bulldog. 9 Hypoglossal activity is also augmented by norepinephrine, 10 although this effect has not been studied as extensively as it has been with serotonin.
Mirtazapine is an antidepressant with a number of actions on the serotonergic and noradrenergic systems. The drug increases both serotonin and norepinephrine by blockade of central α 2 autoreceptors and heteroreceptors. 11, 12 In addition, mirtazapine is a blocker of type 2 and type 3 serotonin receptors. Unlike SSRIs, mirtazapine does not impair sleep quality. 11, 13 The sedating properties are believed to be secondary to the histamine-receptor blockade. The 5-HT 2 receptor-blocking activity may also increase slow-wave sleep. 13 The combination of beneficial actions of mirtazapine on sleep as well as the ability to increase serotonin and norepinephrine makes it a candidate for use in the treatment of obstructive sleep apnea.
The specific effects of mirtazapine administration on genioglossus activity, however, have not been previously studied. A study in rats during natural sleep found that mirtazapine decreased the amount of central apnea and stimulated ventilation without impairing sleep quality. 14 Yet this observation does not directly imply that mirtazapine would decrease obstructive apnea or increase genioglossus activity. Respiratory stimulants (eg, salicylate, acetazolamide, carbon dioxide) tend to decrease obstructive as well as central apnea. [15] [16] [17] Stimulation of ventilation may reduce obstructive apnea by stabilization of neural input to the upper airway muscles 18 rather than by augmenting upper airway muscle activity relative to the respiratory pump muscles. However, because mirtazapine alters serotonergic and noradrenergic neurotransmission, there is reason to believe that the drug might directly affect genioglossus activity independent of other respiratory pump muscles. Indeed, protriptyline, another drug that increases serotonin and norepinephrine (blocks reuptake of norepinephrine and to a lesser extent serotonin), has been shown to increase hypoglossal nerve activity with little effect of phrenic activity when administered intravenously in the decerebrate vagotomized cat. 19 The present study was undertaken to directly test the effect of mirtazapine on genioglossus activity in the rat. We hypothesized that mirtazapine would alter genioglossus activity but that the net effect might depend on the dose administered. The ability of mirtazapine to increase serotonin and norepinephrine and to block 5-HT 3 receptors might be expected to increase genioglossus activity. Alternatively, the 5-HT 2 receptor-blocking actions might be expected to decrease genioglossus activity. Thus, the net effect would depend on the predominant effect, and this could vary with the drug level in the brain (dose related). To test this hypothesis, the effects of mirtazapine on genioglossus and diaphragm electromyogram (EMG) activity at 2 different doses (0.5 mg/kg and 5.0 mg/kg) were studied in the anesthetized rat.
METHODS
All experiments were performed on adult male SpragueDawley rats (362-457 g) obtained from Harlan (Indianapolis, IN, USA). There were 10 animals in each of the 3 groups (control, mirtazapine 0.5 mg/kg, and mirtazapine 5.0 mg/kg). The weights (mean ± SEM) of the animals in the 3 groups were 410 ± 12, 400 ± 10, and 408 ± 13 g, respectively. The animals were housed in the Malcom Randall Veterans Affairs Medical Center animal care facility and exposed to a normal 12-hour light (6 AM to 6 PM) 12-hour dark cycle (6 PM to 6 AM). The Institutional Animal Care and Use Committee approved all experimental procedures.
General Preparation
Animals were anesthetized with an intraperitoneal injection of urethane (1.2-1.4 g/kg) and instrumented with femoral arterial and venous catheters (polyethylene 50 tubing) for recording of arterial pressure and administration of intravenous fluids, respectively. While the animals were in the supine position, a midline incision was made on the ventral surface of the neck, a tracheostomy was performed, and the animal was intubated. Cervical vagus nerves were isolated bilaterally and sectioned just caudal to the insertion of the superior laryngeal nerve (the nodose ganglion was left intact). Vagotomy was performed to eliminate tonic inhibition of genioglossus activity by lung stretch receptors. 20, 21 All animals were spontaneously breathing room air mixed with 100% oxygen. For measurement of diaphragmatic activity, 2 small, (0.003-mm diameter) Teflon-coated, stainless-steel wires with bared tips were inserted subcostally into the right side of the diaphragm through the abdominal musculature. For measurement of genioglossus activity, 2 thin, wire, hook electrodes were inserted into the ventral surface of the tongue, parallel and on each side of the frenulum. Adequate placement of the genioglossus electrodes was verified by electrical stimulation via the electrodes (8-V, 0.4-millisecond pulse width, 30-50 Hz) and observation of tongue protrusion. Body temperature was continuously monitored with a rectal temperature probe (Harvard Apparatus, Holliston, MA, USA) and kept within normal range 38 ± 1 degrees centigrade with a heating blanket. Supplemental anesthesia was given immediately when necessary (0.1 g/kg), as evidenced by fluctuations in blood pressure, heart rate, or respiration during the operation or in response to a pinch of the hind paw.
The arterial catheter was attached to a pressure transducer (Transpac II, Abbott Critical Care, Chicago, IL, USA) connected to an amplifier (7P1 DC Amplifier, Grass Telefactor, West Warwick, RI, USA). The genioglossal and diaphragmatic electromyographic wires with appropriate grounds were connected to high-impedance Grass preamplifier probes and 7P511 amplifiers. The EMG signals were then amplified (20,0000 to 50,0000 times), band-pass filtered (50 Hz-1.0 kHz), rectified, and integrated (MA-821 moving time averager, CWE, Ardmore, Il) to obtain moving time averages using a time constant of 100 milliseconds.
Pulsatile blood pressure and raw and integrated genioglossus and diaphragmatic EMG signals were recorded with an analog digital board and software (Gamma 4.4, Grass-Telefactor) datasampling system and recorded simultaneously. The baseline moving time average genioglossal and diaphragmatic EMG peak amplitudes were adjusted to a value of 1.0 to 3.0 (arbitrary units) at the beginning of the experiment.
Protocol
Data collection began approximately 15 to 20 minutes after the completion of vagotomy, after respiration had stabilized. Baseline blood pressure, diaphragmatic EMG, and genioglossal EMG were sampled continuously for 12 minutes prior to intraperitoneal drug injection and for 3 hours following drug injection. Each animal received an injection of only 1 drug, either vehicle (saline, 0.5 mL), mirtazapine 0.5 mg/kg in 0.5 mL of saline, or mirtazapine 5.0 mg/kg in 0.5 mL saline. An intraperitoneal route of drug administration was specifically chosen so that our results could be compared to the 1 previous study that administered mirtazapine to rats 14 and so that doses similar to those prescribed for oral administration in humans could be evaluated. Arterial blood samples were taken at the end of the monitoring period and analyzed for pH, PCO 2 and PO 2 (iSTAT, Heska Corp, Fort Collins, CO, USA). At the end of the experiment, the animals were euthanized.
Data Analysis
Recording began after the genioglossus activity had stabilized after the vagotomy. Baseline measurements (10-breath averages) were made at 3 minutes, 7 minutes, and 11 minutes after the recording period began, prior to intraperitoneal injection. The results were averaged to obtain baseline values. After drug or saline was adminstered, measurements were made every 10 minutes for 3 hours. The values for each hour were then averaged. All data were analyzed off-line using Gamma Review software (Grass Telefactor). For each measurement period, 10 consecutive breaths were analyzed. The peak phasic and tonic values of the moving time-average signal of the genioglossal and diaphragmatic EMG were manually determined. The average heart rate was determined over the period of time encompassing the 10 breaths by dividing the number of cardiac pulsations in the blood-pressure tracing by the elapsed time. Respiratory rate was determined by dividing the number of respiratory cycles in the first minute of each measurement period by time. Systolic and diastolic blood pressure values were determined for the first 10 blood-pressure pulsations in each measurement time period.
The values of genioglossal EMG, diaphragmatic EMG, heart rate, respiratory rate, systolic blood pressure, and diastolic blood pressure were expressed as a percentage of the baseline period. Significant changes in these variables were determined by performing a repeated-measures analysis using time period (first, second, third) as the repeated variable and drug (saline control, 0.5 mg/kg mirtazapine, 5.0 mg/kg mirtazapine) as the betweengroup variable using a statistical analysis program (Sigma Stat, SysStat Software, Point Richmond, CA, USA). Where appropriate, posthoc comparisons were made with the Student-NeumanKeuls test. Changes were considered significant when P < .05. All data are reported as mean ± SEM.
RESULTS
Administration of mirtazapine at 0.5mg/kg significantly increased peak genioglossal EMG activity compared to control over hours 2 and 3 of the monitoring period ( Figure 1 ). In contrast, mirtazapine at 5.0 mg/kg significantly decreased peak genioglossal EMG activity compared to control over hours 1 and 2 of the monitoring period. The effects of mirtazapine on diaphragmatic activity are shown in Figure 2 . In both mirtazapine-injected groups, peak diaphragmatic EMG was reduced slightly relative to vehicle-treated animals. This reduction in peak diaphragmatic EMG, however, was only significantly different from controls following treatment with the higher-dose mirtazapine (5.0 mg/kg, P < .05). Of note, in the saline-injected animals, peak genioglossal EMG activity tended to decrease over time relative to preinjection levels (Figure 1 ), but peak diaphragmatic EMG remained steady (Figure 2) . The tonic genioglossus and diaphragmatic EMG values did not differ between the 3 treatment groups ( Table 1) .
The baseline values of systolic and diastolic blood pressure, respiratory rate, and heart rate for each group are shown in Table  2 . The corresponding values were not statistically different. The higher-dose mirtazapine significantly (P < .05) reduced systolic blood pressure as a percentage of baseline (Figure 3 ) within the first hour following administration and pressure remained significantly reduced relative to both control and low-dose mirtazapine for the remaining 2 hours. The systolic blood pressures in the control and low-dose mirtazapine groups did not differ. The diastolic blood pressure as a percentage of baseline was also lower in the high-dose mirtazapine group than the other 2 groups, although this difference did not reach significance (P < .06) (Figure 3 The respiratory rate as a percentage of baseline was higher in the 5.0-mg/kg mirtazapine group than the other 2 groups over the first hour, but the heart rate as a percentage of baseline did not differ between the 3 groups at any point in time (Figure 4) . The arterial blood-gas data from the end of the experiment is shown in Table 3 . At the end of the experiment, there was a mild respiratory acidosis in all groups. However, the pH, PCO 2 and PO 2 did not differ between the groups.
DISCUSSION
The interest in the effects of serotonin on upper-airway muscle activity has been generated by the desire to find a pharmacologic treatment for obstructive sleep apnea. Augmentation of upperairway muscle activity by a medication could theoretically prevent upper-airway closure during sleep. This study found that a dose of 0.5 mg/kg of mirtazapine augmented peak genioglossus activity compared to control in the anesthetized, vagotomized, spontaneously breathing rat. In contrast, at the higher dose of 5.0 mg/kg, peak genioglossal EMG activity was lower than control. Peak diaphragmatic EMG activity was significantly reduced by high-dose mirtazapine compared to control, although the percentage decrease was smaller than the decrease in genioglossus activity. These observations suggest that the multifaceted actions of mirtazapine increase peak genioglossus activity only when administered at lower doses. At the higher dose, mirtazapine actually decreased genioglossus activity.
Direct application of serotonin on the hypoglossal nucleus in animal preparations 2, 3 or via dialysis in freely moving animals 4 has been documented to increase hypoglossal or genioglossus activity. Systemic administration of 5-hydroxytryptophan, the immediate precursor of serotonin, also increases hypoglossal 22 or genioglossal activity 23 in the anesthetized rat. However, to date, studies of serotonergic agents in humans have been disappointing. 24, 25 Most studies have focused on SSRIs. Studies have found evidence of modest augmentation in genioglossus activity during wakefulness 26 or non-rapid eye movement sleep 27 with the SSRI paroxetine. However, this medication decreased the apneahypopnea index only during non-rapid eye movement sleep in patients with mild to moderate sleep apnea. 25 Moreover, SSRIs disturb sleep, and no study has shown an improvement in sleep quality.
As norepinephrine also augments genioglossus activity, 10 one might hypothesize that agents increasing both serotonin and norepinephrine might be more effective than SSRIs. Mirtazapine is a novel antidepressant that increases both serotonin and norepinephrine without disturbing sleep quality. The medication is also a blocker of serotonin type-2 and type-3 receptors. The latter effect might be expected to increase genioglossus activity. 8, 9 Increasing Genioglossus Activity- Ondansetron, a 5-HT 3 receptor blocker, has been shown to increase hypoglossal activity in high doses when given systemically but not when administered directly on the hypoglossal nucleus. 8 Ondansetron also decreased sleep-disordered breathing in the English bulldog. 9 However, a trial of ondansetron on moderate obstructive sleep apnea found no benefit. 28 On the other hand, 5-HT 2 receptor blockers might be expected to decrease genioglossus activity. The receptor on the hypoglossal motor nuclei mediating augmentation of serotonin appears to be of the 5-HT 2a type. 5 One might expect the net effect of mirtazapine on genioglossus to depend on the relative importance of its different actions, and these might vary with the level of medication present in the brainstem (dose).
The results of our study demonstrate that, at the lower dose (0.5 mg/kg), mirtazapine increased peak genioglossus activity. Carley et al 14 have shown that mirtazapine at all doses ranging from 0.1 mg/kg to 5.0 mg/kg suppressed central apnea in both non-rapid eye movement and rapid eye movement sleep and increased minute ventilation in freely moving rats. Their study, however, did not report respiratory rate separately from measurement of minute ventilation. There was no effect of dose on the changes in minute ventilation. We did not measure minute ventilation but did find the PCO 2 to be slightly lower, although not significantly, at the end of the experiment in the mirtazapine groups compared to controls. In the higher-dose mirtazapine group, the respiratory rate was also increased compared to control during the first hour of monitoring.
Our experiment does not allow us to determine if the increase in serotonin-norepinephrine or 5-HT 3 blockade (or both) increased genioglossus activity. Veasey and coworkers 9 found that approximately 1 and 2 mg/kg of ondansetron reduced the apnea-hypopnea index during rapid eye movement sleep in the English bulldog. Because systemic administration of ondansetron has been shown to increase hypoglossal activity, 8 this effect on the apnea-hypopnea index may have been secondary to an increase in upper-airway muscle activity. We are not aware of a study comparing the potency of ondansetron and mirtazapine with respect to 5-HT 3 blockade.
In the control group, over the 3 hours of monitoring, the peak diaphragmatic activity tended to increase slightly, to approximately 110% of baseline (Figure 2,) , while peak genioglossus activity in the control group decreased to around 60% of the baseline activity (Figure 1 ). We can offer 2 possible explanations for this finding. First, it is possible that the fall in genioglossus activity represents a subacute adaptation to the effects of vagotomy. All rats were noted to have an immediate and large increase in peak genioglossus activity following vagotomy. We waited a minimum of 10 minutes after vagotomy until acute changes in the breathing pattern and genioglossus activity had stabilized before starting recording and determining the baseline values. However, there could have been a slower component of adaptation to vagotomy over the next several hours. Second, the fall in genioglossus activity from baseline could represent a progressive effect of anesthesia. Anesthesia has been shown to preferentially decrease upper-airway muscle activity. 29 We do not believe that the fall in genioglossus activity in the control group represents a deterioration of the brainstem because blood pressure and heart rate were relatively stable. Nor is there evidence of deterioration of the fine wire electrode recording because, in the lower-dose mirtazapine group, the peak genioglossal EMG activity actually increased over the monitoring period. In any case, we used the same procedure for all groups and, therefore, controlled for the fall in genioglossus activity following vagotomy.
The peak diaphragmatic EMG activity was less than that of the control group in the higher-dose mirtazapine group. As with the effects of mirtazapine on the genioglossus, changes in diaphragm activity could represent competing effects of different actions of the medication. Veasey et al 30 found that ritanserin, a 5-HT 2 blocker, decreased diaphragmatic activity in the English bulldog. In contrast, Richmonds and Hudgel 22 found that ritanserin actually increased both hypoglossal and phrenic activity in the anesthetized rat. Mirtazapine, by increasing serotonin and blocking 5-HT 2 and 5-HT 3 receptors, tends to result in preferential stimulation of 5-HT 1 receptors. Application of 5-HT 1 agonists to the brainstem increases respiratory frequency in decerebrate cats. 31 At the higher dose of mirtazapine, we found evidence of an increase in respiratory frequency over the first hour of monitoring (Figure 4) .
In the study of mirtazapine in naturally sleeping rats, the medication increased ventilation and reduced central apnea. 14 Tidal volume and respiratory rate were not analyzed separately. We did not find a consistent increase in respiratory rate, and peak diaphragmatic EMG was not increased (actually decreased at the higher dose). However, our rats were vagotomized, tracheostomized, anesthetized, and breathing oxygen-enriched air. Thus, our results could be different because of any or all of these differences in experimental technique. The arterial blood gases at the end of the experiment also did not show a higher PCO 2 (actually slightly lower) than control in either mirtazapine group. Hence, it is unlikely that mirtazapine decreased ventilation.
Finally, we acknowledge that there are several limitations of our methodology. First, we studied the anesthetized rat instead of a decerebrate or freely moving animal. As mentioned above, there is a preferential suppression of hypoglossal activity by use of anesthesia. 29 Despite, the use of anesthesia we were able to show an increase in genioglossus activity compared to control with the lower dose of mirtazapine. Second, we studied the effects of mirtazapine in a vagotomized animal. Vagotomy increases phasic genioglossus activity and facilitates measurements. However, it is possible that our results may not generalize to animals (or humans) with an intact vagus nerve. Third, we only studied a 1-log difference in dosage (0.5 and 5.0 mg/kg). It is possible that lower or higher doses have different effects. There may be a narrow therapeutic window and a given dose could have different effects in different patients. Certainly further study is needed to better define the dose effect. Finally, the design of our study allowed us to study only the acute effects of mirtazapine. There certainly could be differences between acute and chronic effects of mirtazapine on the genioglossus. Studies of chronic drug administration in freely moving rats would be needed to determine if the effects we demonstrated have clinical relevance. However, our findings do suggest that mirtazapine at a dose used clinically in humans (0.5 mg/kg) may augment genioglossus activity, and, thus, the medication could have clinical utility. In summary, this investigation demonstrated that, at a dose of mirtazapine similar to that used clinically for depression, genioglossus activity was significantly increased compared to control animals in the anesthetized rat within 2 hours of administration. In contrast, at a higher dose of mirtazapine, genioglossus activity was significantly reduced below control for 2 hours after drug administration. We hypothesize that the differential dose effects were secondary to the predominance of different actions of mirtazapine-some enhancing and others diminishing genioglossus activity.
